Renovate Biosciences is at the forefront of biotechnology, focusing on innovative solutions that enhance both animal and human health. The company specializes in several advanced therapeutic areas, including gene therapy, immunotherapy, and cell therapy. Their gene therapy initiatives aim to rectify genetic defects by delivering therapeutic genes directly to affected cells, potentially offering cures for a variety of genetic disorders. In addition, their immunotherapy platform utilizes engineered immune cells to combat cancer and other diseases, showcasing their commitment to harnessing the immune system's power for therapeutic purposes. Furthermore, their expertise in cell therapy allows for the engineering of cells to target and treat a range of conditions, including cancer and autoimmune disorders.

In the realm of bioengineering, Renovate Biosciences develops novel biomaterials and medical devices that enhance patient outcomes and quality of life. Their regenerative medicine efforts focus on creating exogenous human organs using stem cells, which could provide solutions for previously untreatable conditions. The company also leverages precision pig models for cancer research, facilitating biomarker discovery and the testing of various therapeutic approaches. With over five decades of combined experience, Renovate Biosciences is dedicated to pushing the boundaries of biotechnology, offering custom genetic engineering models and a wide range of swine genetics to support diverse research needs.

United States

RenOVAte Biosciences Inc (RBI) is a Delaware Incorporated, Maryland based animal biotechnology company founded in December 2016. RBI is in the business of performing sophisticated and precision genome editing and genetic engineering in livestock species, to address critical priorities of animal and human health.

Renovate Biosciences

Company Details